Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ADAM9_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ADAM9_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ADAM9_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ADAM9_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ADAM9_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ADAM9_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ADAM9_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ADAM9_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ADAM9_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00425426 | Stomach | GC | response to hydrogen peroxide | 22/1159 | 146/18723 | 9.34e-05 | 1.92e-03 | 22 |
GO:00507146 | Stomach | GC | positive regulation of protein secretion | 21/1159 | 137/18723 | 1.04e-04 | 2.05e-03 | 21 |
GO:00507085 | Stomach | GC | regulation of protein secretion | 33/1159 | 268/18723 | 1.27e-04 | 2.40e-03 | 33 |
GO:00512226 | Stomach | GC | positive regulation of protein transport | 36/1159 | 303/18723 | 1.33e-04 | 2.49e-03 | 36 |
GO:00313316 | Stomach | GC | positive regulation of cellular catabolic process | 46/1159 | 427/18723 | 1.79e-04 | 3.12e-03 | 46 |
GO:00315895 | Stomach | GC | cell-substrate adhesion | 40/1159 | 363/18723 | 2.91e-04 | 4.68e-03 | 40 |
GO:00098966 | Stomach | GC | positive regulation of catabolic process | 50/1159 | 492/18723 | 3.89e-04 | 5.97e-03 | 50 |
GO:0071222 | Stomach | GC | cellular response to lipopolysaccharide | 25/1159 | 209/18723 | 1.21e-03 | 1.38e-02 | 25 |
GO:00457326 | Stomach | GC | positive regulation of protein catabolic process | 26/1159 | 231/18723 | 2.34e-03 | 2.25e-02 | 26 |
GO:0071219 | Stomach | GC | cellular response to molecule of bacterial origin | 25/1159 | 221/18723 | 2.62e-03 | 2.45e-02 | 25 |
GO:00085443 | Stomach | GC | epidermis development | 33/1159 | 324/18723 | 3.43e-03 | 2.96e-02 | 33 |
GO:00099134 | Stomach | GC | epidermal cell differentiation | 23/1159 | 202/18723 | 3.50e-03 | 3.02e-02 | 23 |
GO:00515922 | Stomach | GC | response to calcium ion | 18/1159 | 149/18723 | 4.97e-03 | 3.96e-02 | 18 |
GO:00016675 | Stomach | GC | ameboidal-type cell migration | 44/1159 | 475/18723 | 4.97e-03 | 3.96e-02 | 44 |
GO:00071605 | Stomach | GC | cell-matrix adhesion | 25/1159 | 233/18723 | 5.24e-03 | 4.11e-02 | 25 |
GO:0071216 | Stomach | GC | cellular response to biotic stimulus | 26/1159 | 246/18723 | 5.44e-03 | 4.24e-02 | 26 |
GO:00106345 | Stomach | GC | positive regulation of epithelial cell migration | 20/1159 | 176/18723 | 6.33e-03 | 4.73e-02 | 20 |
GO:0010042 | Stomach | GC | response to manganese ion | 5/1159 | 20/18723 | 6.39e-03 | 4.74e-02 | 5 |
GO:000697911 | Stomach | CAG with IM | response to oxidative stress | 59/1050 | 446/18723 | 7.12e-10 | 1.02e-07 | 59 |
GO:001003811 | Stomach | CAG with IM | response to metal ion | 46/1050 | 373/18723 | 4.33e-07 | 2.43e-05 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADAM9 | SNV | Missense_Mutation | | c.1158N>A | p.Ser386Arg | p.S386R | Q13443 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ADAM9 | SNV | Missense_Mutation | novel | c.1933N>C | p.Asp645His | p.D645H | Q13443 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
ADAM9 | SNV | Missense_Mutation | novel | c.1439N>T | p.Cys480Phe | p.C480F | Q13443 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1PC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ADAM9 | deletion | Frame_Shift_Del | novel | c.1942delN | p.Lys649SerfsTer43 | p.K649Sfs*43 | Q13443 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ADAM9 | deletion | Frame_Shift_Del | novel | c.2429delC | p.Pro810LeufsTer26 | p.P810Lfs*26 | Q13443 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
ADAM9 | SNV | Missense_Mutation | novel | c.1825N>C | p.Ser609Pro | p.S609P | Q13443 | protein_coding | deleterious(0.01) | benign(0.405) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ADAM9 | SNV | Missense_Mutation | | c.2264N>T | p.Arg755Leu | p.R755L | Q13443 | protein_coding | tolerated(0.15) | benign(0.018) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ADAM9 | SNV | Missense_Mutation | | c.1028C>T | p.Ser343Phe | p.S343F | Q13443 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-EX-A1H6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ADAM9 | SNV | Missense_Mutation | | c.475N>C | p.Glu159Gln | p.E159Q | Q13443 | protein_coding | tolerated(0.26) | possibly_damaging(0.629) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ADAM9 | SNV | Missense_Mutation | | c.605N>C | p.Arg202Pro | p.R202P | Q13443 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |